Retatrutide (LY3437943) vs Survodutide (BI 456906)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Retatrutide (LY3437943) and Survodutide (BI 456906) (also searched as Survodutide (BI 456906) vs Retatrutide (LY3437943)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Retatrutide (LY3437943) centers on metabolic, while Survodutide (BI 456906) leans toward metabolic. On indexed research, Survodutide (BI 456906) is ahead (Retatrutide (LY3437943): 0 studies, Preclinical; Survodutide (BI 456906): 1, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Retatrutide (LY3437943) is strongest for metabolic; Survodutide (BI 456906) for metabolic.
- •Evidence: Retatrutide (LY3437943) Preclinical (0 studies) vs Survodutide (BI 456906) Human clinical (1).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Retatrutide (LY3437943) vs Survodutide (BI 456906): side-by-side
| Metric | Retatrutide (LY3437943) | Survodutide (BI 456906) |
|---|---|---|
| Class | Weight Loss | Weight Loss |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Human clinical |
| Studies indexed | 0 | 1 |
| Research level | Extensively Studied | Extensively Studied |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 0.0 | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 5.0▲ | 5.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 0.0 |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Retatrutide (LY3437943) | Survodutide (BI 456906) |
|---|---|---|
| Mechanism | Triple GLP-1 / GIP / glucagon receptor agonist | — |
| Route | Subcutaneous injection | — |
| Half-life | ~6 days | — |
| Duration of action | Weekly dosing (investigational) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Retatrutide (LY3437943)?
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Full Retatrutide (LY3437943) profile, mechanism & studies →What is Survodutide (BI 456906)?
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Full Survodutide (BI 456906) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Metabolic | Even | Both ~5.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Retatrutide (LY3437943) and Survodutide (BI 456906)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Retatrutide (LY3437943) vs Survodutide (BI 456906): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Retatrutide (LY3437943) has 0 approved studies indexed (Preclinical), and Survodutide (BI 456906) has 1 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Retatrutide (LY3437943) or Survodutide (BI 456906) better?
It depends on your goal. Retatrutide (LY3437943) is strongest for metabolic; Survodutide (BI 456906) for metabolic. Survodutide (BI 456906) has more indexed studies (1). See the goal-by-goal breakdown above.
Is Retatrutide (LY3437943) or Survodutide (BI 456906) better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Which has more research, Retatrutide (LY3437943) or Survodutide (BI 456906)?
Retatrutide (LY3437943) has 0 approved studies indexed (Preclinical); Survodutide (BI 456906) has 1 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Retatrutide (LY3437943) and Survodutide (BI 456906)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Retatrutide (LY3437943) vs Survodutide (BI 456906)?
Retatrutide (LY3437943): no community-reported effects logged yet. Survodutide (BI 456906): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Retatrutide (LY3437943) or Survodutide (BI 456906) FDA-approved?
Retatrutide (LY3437943) is a research-use compound and is not FDA-approved. Survodutide (BI 456906) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Survodutide (BI 456906) better than Retatrutide (LY3437943)?
For metabolic, Survodutide (BI 456906) has the edge; for metabolic, Retatrutide (LY3437943) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Retatrutide (LY3437943) and Survodutide (BI 456906) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.